Wenda Pharma Introduces Breakthrough NHWD-870 Therapy for Treating NUT Carcinoma
Wenda Pharma has introduced NHWD-870 HCl for the treatment of advanced NUT carcinoma, a rare and highly aggressive cancer with limited treatment options and poor survival outcomes.
NHWD-870 HCl is a novel oral bromodomain and extra-terminal (BET) inhibitor designed to inhibit BET proteins involved in tumour growth and progression. The therapy has received Breakthrough Therapy Designation from China's National Medical Products Administration (NMPA) for the treatment of patients with advanced thoracic NUT carcinoma who have failed prior chemotherapy.
The designation is supported by results from a Phase II clinical study involving 40 evaluable patients with advanced NUT carcinoma. Among patients with advanced thoracic NUT carcinoma, the therapy achieved an objective response rate (ORR) of 45%, while the median overall survival (mOS) reached 9.33 months, demonstrating an improvement compared with conventional chemotherapy. The treatment was generally well tolerated, with preliminary safety data indicating favourable tolerability.
NUT carcinoma is a rare, poorly differentiated cancer caused by NUTM1 gene rearrangements. The disease progresses rapidly and is associated with a median survival of approximately 6.5 months. Due to its rarity and non-specific clinical presentation, diagnosis is often delayed, and there are currently no globally approved targeted therapies available for the disease.
The NMPA Breakthrough Therapy Designation is intended to accelerate the development and regulatory review of innovative medicines that demonstrate significant clinical benefit over existing treatment options.
NHWD-870 HCl continues to be evaluated in ongoing clinical studies to further establish its long-term efficacy and safety.
